US-based ARS’s nasal spray to treat allergic reactions gets FDA nod
ARS Pharmaceuticals, a US-based biopharmaceutical company, got the nationâs drug regulatorâs approval for a nasal spray to treat allergic reactions in adult and.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
ARS Pharmaceuticals, a US-based biopharmaceutical company, got the nationâs drug regulatorâs approval for a nasal spray to treat allergic reactions in adult and.
Lykos Therapeuticsâs ecstasy drug or midomafetamine capsules for the treatment of post-traumatic stress disorder in adults was rejected by the US drug regulatory.
When parents share unflattering or embarrassing images, it can lead to feelings of humiliation and a distorted self-image. Children may struggle with their.
Citius Pharmaceuticals, Inc., a US-based biotechnology company, got a green light from the countryâs drug regulator for its immunotherapy treatment for a rare.
US drugmaker Purdue Pharmaâs injection to treat opioid overdose in adults and patients 12 years or older, got the countryâs drug regulatorâs approval.
Vaccinations have saved more than 1.6 million lives in the WHO European Region and Covid-19 is lurking around the world menacingly with its.
Merck has stopped an end-stage combination immunotherapy trial for a lung cancer condition, following recommendations of an independent data monitoring committee, which indicated.
Switzerlandâs Novartis AG has received accelerated approval from the USFDA for its drug to reduce elevated levels of proteins in the urine of.
Danish biotechnology company, Pharmacosmos A/S will buy US-based G1 Therapeutics Inc., for $405 million to expand its global commercial portfolio in haematology.
The WHOâs event-based surveillance system has reported that at least 40 athletes participating in the Olympic Games in France had tested positive for.